Criteria for unsupervised use.

(a) To limit the potential for diversion of medication used for the treatment of opioid use disorder to the illicit market, medication dispensed to a client for unsupervised use shall be subject to the deleted text begin following deleted text end requirements deleted text begin : deleted text end new text begin of this subdivision. new text end

deleted text begin (1) deleted text end Any client in an opioid treatment program may receive a single unsupervised use dose for a day that the clinic is closed for business, including Sundays and state and federal holidays deleted text begin ; and deleted text end new text begin . new text end

deleted text begin (2) other treatment program decisions on dispensing medications used for the treatment of opioid use disorder to a client for unsupervised use shall be determined by the medical director. deleted text end

(b) deleted text begin In determining whether a client may be permitted unsupervised use of medications, a physician deleted text end new text begin A practitioner new text end with authority to prescribe must deleted text begin consider deleted text end new text begin review and document new text end the criteria in this paragraph deleted text begin . The criteria in this paragraph must also be considered deleted text end new text begin and paragraph (c) new text end when determining whether dispensing medication for a client's unsupervised use is appropriate to new text begin implement, new text end increase new text begin , new text end or deleted text begin to deleted text end extend the amount of time between visits to the program. The criteria are:

(1) absence of recent abuse of drugs including but not limited to opioids, non-narcotics, and alcohol;

(2) regularity of program attendance;

(3) absence of serious behavioral problems at the program;

(4) absence of known recent criminal activity such as drug dealing;

(5) stability of the client's home environment and social relationships;

(6) length of time in comprehensive maintenance treatment;

(7) reasonable assurance that unsupervised use medication will be safely stored within the client's home; and

(8) whether the rehabilitative benefit the client derived from decreasing the frequency of program attendance outweighs the potential risks of diversion or unsupervised use.

(c) The determination, including the basis of the determination must be documented in the client's medical record.